Patent · US Active

Anti-MUC16 antibodies

US10941208B2 · kind B2 · utility

1Cited by

0References

2Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Lauric Haber · Rye Brook, US
Eric Smith · New York, US
Marcus Kelly · New York, US
Jessica R. Kirshner · New York, US
Sandra Coetzee · White Plains, US
Alison Crawford · Dobbs Ferry, US
Thomas Nittoli · Pearl River, US
Yashu Liu · Burlingame, US

Key dates

Filing date	Sep 22, 2017
Grant date	Mar 9, 2021
Priority date	—
Expiry date	Sep 10, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/705
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.